Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series
Open Access
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 25, 98-101
Abstract
No abstract availableKeywords
Funding Information
- Ensign Endowment for Gynecologic Cancer Research
This publication has 10 references indexed in Scilit:
- Cancer statistics, 2018CA: A Cancer Journal for Clinicians, 2018
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issuesInternational Journal of Clinical Oncology, 2016
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancerOncotarget, 2016
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Neoantigens in cancer immunotherapyScience, 2015
- Overcoming platinum resistance in ovarian carcinomaExpert Opinion on Investigational Drugs, 2010
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992